Pfizer's Lorbrena Shows 81% Reduction in Lung Cancer Progression in Five-Year Study

May 31, 2024, 02:12 PM

Pfizer's LORBRENA® CROWN study has demonstrated significant efficacy in treating a rare type of ALK-positive advanced lung cancer. The study shows that a majority of patients are living beyond five years without disease progression. The drug, Lorbrena, has reduced lung cancer progression by 81%, offering a substantial improvement in patient outcomes. This rare type of lung cancer is usually seen in nonsmokers. The study was highlighted by Pfizer $PFE and reported via @matthewherper at #ASCO24.